Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
KYMR submitted a Form 144 reporting a proposed sale of 11,741 shares of Common Stock, dated 06/17/2026. The filing lists recent open-market dispositions by holders in April 2026.
The notice shows multiple prior sales, including Atlas Venture Fund X selling 2,750 shares for $247,765.57 on 04/15/2026 and Bruce Booth selling 5,900 shares for $530,746.25 on 04/22/2026. The filing identifies the securities as Common Stock and references stock-option-derived shares.
KYMR Rule 144 notice: Morgan Stanley Smith Barney LLC states 66,893 shares of common stock are to be sold following an exercise of stock options on 06/17/2026 for cash. The filing also lists multiple 10b5-1 sales by Jeremy Chadwick earlier in 2026, including a 91,250-share sale on 03/23/2026 for $7,063,733.26 and other transactions in March–May 2026.
Kymera Therapeutics, Inc. reported that Chief Operating Officer Jeremy Chadwick has communicated his intention to retire and submitted his resignation as COO on June 5, 2026. He will remain an employee of the company as an advisor until November 2026 to support the transition.
The company states that Mr. Chadwick resigned for personal reasons and that his decision was not the result of any disagreement with Kymera’s practices or policies. The filing is framed as an orderly leadership change with continued advisory involvement over several months.
Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 12,653 shares of common stock at an exercise price of $2.08 per share. The corresponding stock option for 12,653 shares was fully exercised and now shows zero derivative shares remaining. Following this transaction, Jacobs holds 260,241 shares of Kymera Therapeutics common stock directly, with no related sale or tax-withholding disposition reported in this filing.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported selling 17,184 shares of common stock in open-market transactions. The sales occurred on May 26–27, 2026 at weighted-average prices within ranges from about $77.99 to $82.15 per share. A footnote explains that the shares were required to be sold to cover tax withholding obligations tied to vesting restricted stock units and that these sales were automatic, not at his discretion. The transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 44,018 Kymera shares.
Morgan Stanley Smith Barney LLC reports Rule 144 notices of proposed sales of Common Stock by Jeremy Chadwick under pre-arranged 10b5-1 plans. The excerpt lists multiple sale dates in March–April 2026 with individual share counts and gross proceeds per transaction.
Kymeta Therapeutics, Inc. reported proposed and recent transactions involving Common Stock. The filing lists shares acquired upon vesting of Restricted Stock Units on 05/22/2026 and multiple 10b5-1 sales by Jeremy Chadwick between 03/02/2026 and 04/22/2026, with individual sale sizes shown in the excerpt.
The excerpt shows specific sale entries such as 91,250 shares on 03/23/2026 and other transactions ranging from 300 to 91,250 shares, with associated gross proceeds listed for many trades.
Kymera Therapeutics director Pamela Esposito exercised stock options to acquire 1,000 shares of Common Stock at an exercise price of $31.20 per share. After the transaction, she held 1,000 Common shares directly and 9,000 stock options with a $31.20 exercise price expiring on June 18, 2034. The filing notes that the shares underlying this option grant are fully vested and exercisable.
Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.08 per share. Following this transaction, he directly holds 247,588 shares of common stock and 12,653 stock options that remain outstanding and expire on August 28, 2029.
Kymera Therapeutics: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 5,460,257 shares of common stock, equal to 6.7% as of 03/31/2026. The filing "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
The filing lists sole voting power of 5,318,875 shares and sole dispositive power of 5,460,257 shares. The signature block is dated 05/15/2026.